Media
Obesity-associated cancers tripled nationwide over past two decades
SAN FRANCISCO—Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
The study, which examined more than 33,000 deaths from obesity-associated cancers, revealed sharp increases in cancer deaths, especially among women, older adults, Native Americans and Black Americans. […]
A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer
2025 Cornelius A phase 1 safety stydy of evexomostat in patients with late-stage cancer
$1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor ‘Evexomostat’
Cambridge, MA (USA) and Brisbane (Australia) – Queensland University of Technology (QUT) in Brisbane, Australia, together with SynDevRx, Inc., a leader in polymer-drug conjugates for cancer and for metabolic dysfunction are honored to announce the receipt of a $1.2 million grant from the US Department of Defense (DoD) for continued research on evexomostat, SynDevRx’s novel
AACR Journal MCT Publishes Initial Disclosure Article on Evexomostat/SDX-7320
Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti- Metastatic Activity Methionine aminopeptidase type 2 (MetAP2) is a ubiquitous, evolutionarily conserved metalloprotease fundamental to protein biosynthesis which catalyzes removal of the N-terminal methionine residue from nascent polypeptides. MetAP2 is an attractive target for cancer therapeutics based upon its over-expression in […]
Amelia-1 Clinical Trial Fully Open To Recruitment, 1st Patient Data on Combination Study with PI3K Inhibitor and SERD
SynDevRx, Inc. today announced the opening of the Amelia-1 study and data from the first patient treated in its Phase 1b/2 clinical study testing the novel MetAP2 inhibitor evexomostat (aka SDX-7320) in combination with the PI3K inhibitor alpelisib (Piqray ) and the estrogen receptor degrader (SERD) drug fulvestrant (Faslodex®) in breast cancer patients with metastatic disease
New Experiment Treatment for Prostate Cancer Revealed at AACR
SDX AACR 2023 poster 05Apr 2023.pptxPRESS RELEASE APR 14, 2023 08:00 EDT Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. New research datan to be presented at AACR 2023 in Orlando, FL
1 Broadway Fl. 14, Cambridge, MA 02142
© 2025 Copyright SynDevRx All rights reserved. Privacy Policy | Terms of Use